New data show first-line triplet regimen of pembrolizumab, Herzuma® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer
Retrieved on:
Friday, May 29, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, Antineoplastic drugs, Genentech, RTT, Immunology, Cancer treatments, Trastuzumab, HER2/neu, Pembrolizumab, Stomach cancer, Trastuzumab emtansine, metastatic (advanced) gastric cancer2,3,4,5, Herzuma® (biosimilar trastuzumab)6, Celltrion Healthcare
Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma (biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC).
Key Points:
- Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma (biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC).
- Gastric cancer is a leading cause of cancer-related deaths worldwide, with over a million new cases of gastric cancer diagnosed each year.
- Clinical trials have evaluated trastuzumab in combination with chemotherapy as first-line treatment for metastatic (advanced) gastric cancer.
- Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2 positive advanced gastric cancer (AGC).